地塞米松、FK-506和CX-659s对TARC产生的调控作用研究  

Regulatory Effect of Dexamethasone,Fk-506 and CX-659s on TARC

作　　者：于彬[1] 方素萍[1] 刘翔[2] 宋坪[1] 董茂盛[2] 

机构地区：[1]中国中医科学院广安门医院国际医疗部,北京100053 [2]中国人民解放军第二炮兵总医院肝胆胃肠研究所,北京100088

出　　处：《中国药业》2012年第20期21-23,共3页China Pharmaceuticals

基　　金：中国中医科学院广安门医院所级课题;项目编号:81373

摘　　要：目的研究地塞米松、他克莫司(FK-506)和CX-659s对胸腺活化调节趋化因子(TARC/CCL17)产生的调控作用。方法运用ELISA方法分别研究了3种药物对人角质形成细胞株——HaCaT细胞和人成纤维细胞株——NG1RGB细胞的TARC表达作用的影响。结果 3种药物对于HaCaT细胞中TARC的表达,10-9～10-5 mol/L地塞米松显示明显的抑制作用;对于IFN-γ刺激下HaCaT细胞产生TARC水平,10-12～10-6 mol/L地塞米松、10-12～10-6 mol/L的FK-506均表现为明显的抑制作用(P<0.05或P<0.01);CX-659s显示明显抑制NG1RGB细胞中TARC水平,且具有浓度依赖性(P<0.01)。3种免疫抑制剂分别在不同条件下抑制皮肤角质形成细胞和/或成纤维细胞的TARC表达。结论这些药物明显抑制TARC在皮肤角质形成细胞和成纤维细胞的表达,因此认为角质形成细胞和成纤维细胞可能在病理状态下通过促进CCR4+T细胞向炎症部位的游走,参与免疫调控作用。Objective To study the regulatory effect generated by dexamethasone,tacrolimus （FK506） and CX- 659s on thymus activa- tion regulated ehemokine （TARC/CCL17）. Methods The ELISA method was adopted to study the influence of these 3 kinds of drug on the TARC expression role of human keratinocytes cell line- HaCaT cell and fibroblasts eel1 line- NG1RGB cell. Results For TARC expression of HaCaT cell,10^-9 -10^- 5 mol/L dexamethasone displayed the obviously inhibiting effect;for HaCaT producing TARC level under IFN-γ stimulation,10^-2- 10^-6 mol/L dexamethasone and 10^-12- 10^-6 mol/L FK-506 all revealed the obvious inhibiting role （P 〈 0. 05 or P 〈 0.01）;CX-659s demonstrated the obvious inhibition on TARC level in NG1RGB with concentration dependency （P 〈 0.01）. 3 kinds of immunosuppressive agents inhibited the TARC expression of keratinocytes and/or fibroblasts under different conditions. Conclusion These immunosuppressive drugs obviously suppress the TARC expression in keratinocytes and fibrob- lasts. Therefore, it is suggested that both keratinocytes and fibroblasts might participate in the immunoregulation role by promoting CCR4＋T cells migration to the inflammatory position under the pathological condition.

关 键 词：地塞米松 FK-506 CX-659s 胸腺活化调节趋化因子 角质形成细胞 成纤维细胞 

分 类 号：R965[医药卫生—药理学] R979.5[医药卫生—药学]